Roflumilast
Indication
Treating chronic obstructive pulmonary disease (NICE TA461)
NICE TA461 - Roflumilast for treating chronic obstructive pulmonary disease
Amber level 0
Brand:
Daxas®
Nice TA:
461
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Respiratory system
Background
Roflumilast, as an add-on to bronchodilator therapy, is recommended as an option for treating severe chronic obstructive pulmonary disease in adults with chronic bronchitis, only if:
•the disease is severe, defined as a forced expiratory volume in 1 second (FEV1) after a bronchodilator of less than 50% of predicted normal, and
•the person has had 2 or more exacerbations in the previous 12 months despite triple inhaled therapy with a long-acting muscarinic antagonist, a long-acting beta-2 agonist and an inhaled corticosteroid.
Treatment with roflumilast should be started by a specialist in respiratory medicine.
Recommendation
LSCMMG Recommendation:
Amber level 0
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist
Supporting documents: